Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M, SHINE Investigators

Open source

DOI: 10.1056/nejmoa2201817
Published: 2022 Jun 30
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2201817,
  title = {Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.},
  author = {Wang ML and Jurczak W and Jerkeman M and Trotman J and Zinzani PL and Belada D and Boccomini C and Flinn IW and Giri P and Goy A and Hamlin PA and Hermine O and Hernández-Rivas JÁ and Hong X and Kim SJ and Lewis D and Mishima Y and Özcan M and Perini GF and Pocock C and Song Y and Spurgeon SE and Storring JM and Walewski J and Zhu J and Qin R and Henninger T and Deshpande S and Howes A and Le Gouill S and Dreyling M and SHINE Investigators},
  year = {2022},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2201817},
  url = {https://doi.org/10.1056/nejmoa2201817}
}

RIS

TY  - JOUR
TI  - Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
AU  - Wang ML
AU  - Jurczak W
AU  - Jerkeman M
AU  - Trotman J
AU  - Zinzani PL
AU  - Belada D
AU  - Boccomini C
AU  - Flinn IW
AU  - Giri P
AU  - Goy A
AU  - Hamlin PA
AU  - Hermine O
AU  - Hernández-Rivas JÁ
AU  - Hong X
AU  - Kim SJ
AU  - Lewis D
AU  - Mishima Y
AU  - Özcan M
AU  - Perini GF
AU  - Pocock C
AU  - Song Y
AU  - Spurgeon SE
AU  - Storring JM
AU  - Walewski J
AU  - Zhu J
AU  - Qin R
AU  - Henninger T
AU  - Deshpande S
AU  - Howes A
AU  - Le Gouill S
AU  - Dreyling M
AU  - SHINE Investigators
PY  - 2022
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2201817
UR  - https://doi.org/10.1056/nejmoa2201817
ER  -

APA

ML, W., W, J., M, J., J, T., PL, Z., D, B., C, B., IW, F., P, G., A, G., PA, H., O, H., JÁ, H., X, H., SJ, K., D, L., Y, M., M, Ö., GF, P., C, P., Y, S., SE, S., JM, S., J, W., J, Z., R, Q., T, H., S, D., A, H., S, L. G., M, D., & Investigators, S. (2022). Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2201817

Source records

pubmed · retrieved 2026-09-26T02:09:03.441Z